𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis

✍ Scribed by Lorenz C. Hofbauer; Armin E. Heufelder

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
311 KB
Volume
44
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Receptor activator of nuclear factor-κB
Receptor activator of nuclear factor-κB ligand and osteoprotegerin : Potential implications for the pathogenesis and treatment of malignant bone diseases
✍ Lorenz C. Hofbauer; Andreas Neubauer; Armin E. Heufelder 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

## Background: The current review summarizes the roles of the ligand, receptor activator of nuclear factor-kappab ligand (rankl), its receptor, receptor activator of nuclear factor-kappab (rank), and its decoy receptor, osteoprotegerin (opg), on osteoclast biology and bone resorption. furthermore,

High levels of osteoprotegerin and solub
High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatment
✍ Maria Ziolkowska; Mariola Kurowska; Anna Radzikowska; Grazyna Luszczykiewicz; Pi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

## Abstract ## Objective To test the hypotheses that 1) proinflammatory cytokines affect osteoprotegerin (OPG) and soluble receptor activator of nuclear factor κB ligand (sRANKL) production and therefore the OPG and sRANKL levels differ in rheumatoid arthritis (RA) patients in comparison with heal

Receptor Activator of Nuclear Factor Kap
Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Modulates the Expression of Genes Involved in Apoptosis and Cell Cycle in Human Osteoclasts
✍ Erika Rimondi; Marina Zweyer; Enrico Ricci; Roberto Fadda; Paola Secchiero 📂 Article 📅 2007 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 307 KB

## Abstract It has been clearly established that receptor activator of nuclear factor kappa B ligand (RANKL) is a key cytokine involved in the differentiation of osteoclastic precursors of the monocytic/macrophagic lineage. However, relatively little information is available on the ability of RANKL

Role of IκBα and IκBβ in the biphasic nu
Role of IκBα and IκBβ in the biphasic nuclear translocation of NF-κB in TNFα-stimulated astrocytes and in neuroblastoma cells
✍ Iris Kemler; Adriano Fontana 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB

In infectious diseases of the central nervous system astrocytes respond to inflammatory cytokines like tumor necrosis factor ␣ (TNF␣) by activation of the transcription factor NF-B, mediated by the proteolysis of its inhibitors IB␣ and IB␤. We studied the kinetics of NF-B induction by TNF␣ in primar

The antirheumatic drug leflunomide inhib
The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand–stimulated induction of nuclear factor of activated T cells c1
✍ Makoto Urushibara; Hiroshi Takayanagi; Takako Koga; Sunhwa Kim; Miho Isobe; Yasu 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB

## Abstract ## Objective Suppression of bone destruction is required as part of an effective therapeutic strategy for autoimmune arthritis. Although numerous antirheumatic drugs are in clinical use, little is known about whether they inhibit bone destruction by acting on activated T cells or other